Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Autoimmune Disorders

  Free Subscription

Articles published in Acta Neurol Scand

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    November 2022
  1. ZHAO N, Chang SH, Zhang QX, Zhang LJ, et al
    Clinical features of Guillain-Barre syndrome with anti-neurofascin 155 antibody.
    Acta Neurol Scand. 2022;146:553-561.
    PubMed     Abstract available

  2. PACHECO-BARRIOS K, Navarro-Flores A, de Melo PS, Rebello-Sanchez I, et al
    Neuroleptic intolerance in the context of anti-N-methyl-D-aspartate receptor encephalitis: A systematic review and synthesis of global case reports.
    Acta Neurol Scand. 2022;146:410-428.
    PubMed     Abstract available

  3. KIM JE, Yoon BA, Kim YH, Kim JK, et al
    Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
    Acta Neurol Scand. 2022;146:604-609.
    PubMed     Abstract available

    October 2022
  4. LI G, Liu X, Yu T, Ren J, et al
    Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.
    Acta Neurol Scand. 2022 Oct 19. doi: 10.1111/ane.13717.
    PubMed     Abstract available

    September 2022
  5. MONTANES-MASIAS B, Bort-Roig J, Pascual JC, Soler J, et al
    Online psychological interventions to improve symptoms in multiple sclerosis: A systematic review: Online psychological interventions in Multiple Sclerosis.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13709.
    PubMed     Abstract available

  6. CUCE I, Altun Y
    Validity and reliability characteristics of the Silhouettes Fatigue Scale in measuring multiple sclerosis-related fatigue in Turkish-speaking adults.
    Acta Neurol Scand. 2022 Sep 19. doi: 10.1111/ane.13708.
    PubMed     Abstract available

  7. ANDREU-CARAVACA L, Ramos-Campo DJ, Chung LH, Manonelles P, et al
    Effects of fast-velocity concentric resistance training in people with multiple sclerosis: A randomized controlled trial.
    Acta Neurol Scand. 2022 Sep 9. doi: 10.1111/ane.13704.
    PubMed     Abstract available

  8. SILVA GD, Castrillo BB, Apostolos-Pereira SL, Callegaro D, et al
    Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
    Acta Neurol Scand. 2022 Sep 2. doi: 10.1111/ane.13697.
    PubMed     Abstract available

    August 2022
  9. MAGALHAES JE, Sampaio-Rocha-Filho PA
    Reply: Neurological disease in pregnant females with COVID-19 may not only be attributable to SARS-CoV-2.
    Acta Neurol Scand. 2022;146:201-202.

    July 2022
  10. MAHAMUD Z, Burman J, Zelano J
    Temporal trends of epilepsy in multiple sclerosis.
    Acta Neurol Scand. 2022 Jul 18. doi: 10.1111/ane.13671.
    PubMed     Abstract available

  11. MACHADO A, Murley C, Hillert J, Alexanderson K, et al
    Self-employment, sickness absence, and disability pension in multiple sclerosis.
    Acta Neurol Scand. 2022 Jul 4. doi: 10.1111/ane.13664.
    PubMed     Abstract available

    June 2022
  12. HAYAT S, Asad A, Hasan I, Jahan I, et al
    Nucleotide oligomerization domain polymorphism confers no risk to Guillain-Barre syndrome.
    Acta Neurol Scand. 2022 Jun 2. doi: 10.1111/ane.13649.
    PubMed     Abstract available

    May 2022
  13. OZAKBAS S, Piri Cinar B, Baba C, Kosehasanogullari G, et al
    Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
    Acta Neurol Scand. 2022;145:557-564.
    PubMed     Abstract available

    April 2022
  14. ZHAO YY, Wang HX, Wang M, Yuan B, et al
    Relapse factors of patients of anti-N-methyl-D-aspartate receptor encephalitis.
    Acta Neurol Scand. 2022;145:434-441.
    PubMed     Abstract available

  15. SUN Y, Ren G, Ren J, Shan W, et al
    The prognosis of late-onset anti-N-methyl-D-aspartate receptor encephalitis in China.
    Acta Neurol Scand. 2022;145:449-455.
    PubMed     Abstract available

  16. CABREIRA V, Dias L, Fernandes B, Aires A, et al
    Tocilizumab for severe refractory primary central nervous system vasculitis: A center experience.
    Acta Neurol Scand. 2022;145:479-483.
    PubMed     Abstract available

    March 2022
    Comment on comorbidities in older patients with myasthenia gravis.
    Acta Neurol Scand. 2022 Mar 20. doi: 10.1111/ane.13606.

    February 2022
  18. PARK JS, Eah KY, Park JM
    Epidemiological profile of myasthenia gravis in South Korea using the national health insurance database.
    Acta Neurol Scand. 2022 Feb 9. doi: 10.1111/ane.13596.
    PubMed     Abstract available

    Very late onset of myasthenia gravis. Comment: Comorbidities in older patients with myasthenia gravis.
    Acta Neurol Scand. 2022 Feb 7. doi: 10.1111/ane.13588.

    January 2022
  20. WELD-BLUNDELL IV, Grech L, Learmonth YC, Marck CH, et al
    Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review.
    Acta Neurol Scand. 2022 Jan 17. doi: 10.1111/ane.13574.
    PubMed     Abstract available

  21. SOBIESZCZUK E, Napiorkowski L, Szczudlik P, Kostera-Pruszczyk A, et al
    Myasthenia gravis-treatment and severity in nationwide cohort.
    Acta Neurol Scand. 2022 Jan 4. doi: 10.1111/ane.13576.
    PubMed     Abstract available

    Neurological side effects of SARS-CoV-2 vaccinations.
    Acta Neurol Scand. 2022;145:5-9.
    PubMed     Abstract available

    December 2021
  23. LAHOZ FERNANDEZ PE, Miranda Pereira J, Fonseca Risso I, Baleeiro Rodrigues Silva P, et al
    Guillain-Barre syndrome following COVID-19 vaccines: A scoping review.
    Acta Neurol Scand. 2021 Dec 29. doi: 10.1111/ane.13575.
    PubMed     Abstract available

    November 2021
  24. SMYRKE N, Dunn N, Murley C, Mason D, et al
    Standardized mortality ratios in multiple sclerosis: Systematic review with meta-analysis.
    Acta Neurol Scand. 2021 Nov 24. doi: 10.1111/ane.13559.
    PubMed     Abstract available

  25. THEODORSDOTTIR A, Larsen PV, Nielsen HH, Illes Z, et al
    Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis.
    Acta Neurol Scand. 2021 Nov 19. doi: 10.1111/ane.13554.
    PubMed     Abstract available

  26. CHAABAN L, Safwan N, Moussa H, El-Sammak S, et al
    Central vein sign: A putative diagnostic marker for multiple sclerosis.
    Acta Neurol Scand. 2021 Nov 18. doi: 10.1111/ane.13553.
    PubMed     Abstract available

  27. KLIMIEC-MOSKAL E, Quirke M, Leite MI
    Comorbidities in older patients with myasthenia gravis - Comparison between early- and late-onset disease.
    Acta Neurol Scand. 2021 Nov 8. doi: 10.1111/ane.13549.
    PubMed     Abstract available

  28. CONTRERAS JP, Salinas R, Vidal C, Hoffmeister L, et al
    Validation of Spanish version of 15-item myasthenia gravis quality-of-life questionnaire.
    Acta Neurol Scand. 2021;144:546-552.
    PubMed     Abstract available

    October 2021
  29. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on common multiple sclerosis symptoms.
    Acta Neurol Scand. 2021 Oct 22. doi: 10.1111/ane.13540.
    PubMed     Abstract available

    September 2021
  30. KAUR H, Sureshbabu S, Mittal GK, Joseph M, et al
    Catastrophic health expenditure in patients with Guillain Barre syndrome: Retrospective study.
    Acta Neurol Scand. 2021 Sep 1. doi: 10.1111/ane.13523.
    PubMed     Abstract available

    August 2021
  31. MARIC G, Pekmezovic T, Tamas O, Veselinovic N, et al
    Impact of comorbidities on the disability progression in multiple sclerosis.
    Acta Neurol Scand. 2021 Aug 20. doi: 10.1111/ane.13516.
    PubMed     Abstract available

  32. TELJAS C, Bostrom I, Marrie RA, Landtblom AM, et al
    Validating the diagnosis of multiple sclerosis using Swedish administrative data in Varmland County.
    Acta Neurol Scand. 2021 Aug 6. doi: 10.1111/ane.13514.
    PubMed     Abstract available

    July 2021
  33. JOHANSSON K, Wasling P, Axelsson M
    Fatigue, insomnia and daytime sleepiness in multiple sclerosis versus narcolepsy.
    Acta Neurol Scand. 2021 Jul 19. doi: 10.1111/ane.13497.
    PubMed     Abstract available

    June 2021
  34. ZHUKOVSKY C, Herman S, Wiberg A, Cunningham JL, et al
    Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-beta treatment.
    Acta Neurol Scand. 2021;143:602-607.
    PubMed     Abstract available

    May 2021
  35. LANDTBLOM AM, Berntsson SG, Bostrom I, Iacobaeus E, et al
    Multiple sclerosis and COVID-19: The Swedish experience.
    Acta Neurol Scand. 2021 May 24. doi: 10.1111/ane.13453.
    PubMed     Abstract available

  36. TARAKCI E, Tarakci D, Hajebrahimi F, Budak M, et al
    Supervised exercises versus telerehabilitation. Benefits for persons with multiple sclerosis.
    Acta Neurol Scand. 2021 May 7. doi: 10.1111/ane.13448.
    PubMed     Abstract available

    April 2021
  37. FEASEL CD, Sandroff BM, Motl RW
    Aerobic reserve capacity in multiple sclerosis-Preliminary evidence.
    Acta Neurol Scand. 2021 Apr 29. doi: 10.1111/ane.13441.
    PubMed     Abstract available

  38. SAIED Z, Rachdi A, Thamlaoui S, Nabli F, et al
    Myasthenia gravis and COVID-19: A case series and comparison with literature.
    Acta Neurol Scand. 2021 Apr 29. doi: 10.1111/ane.13440.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.